Home | Find A Doctor | Contact Us

 

Calistoga: A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents.


Principal Investigator: Michael Grossbard, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
CAL‑101 is an investigational drug. CAL-101 blocks some of the cell functions that cause indolent Non-Hodgkin Lymphoma (iNHL), a type of cancer, to grow and survive.  By blocking these functions, CAL-101 may reduce or prevent iNHL from growing and surviving. The purpose of this study is to provide more information about whether CAL-101 is safe and effective for treating people with iNHL once their iNHL has become difficult to control with available therapies. CAL-101 is used in this study as part of a research process to find out if it could eventually be approved for more general use in persons with iNHL.


Eligibility and Treatment Plan:

  • Male and female of at least 18 years old
  • Histologically confirmed diagnosis of B-cell indolent Non-Hodgkin  Lymphoma (iNHL)
  • Prior treatment with ≥2 prior chemotherapy
  • Discontinuation of all other therapies (including radiotherapy or chemotherapy) for the treatment of iNHL 3 weeks before initiation of study treatment

Please call for more information.

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System